Logo image of ARD

Ardagh Group SA (ARD) Stock Fundamental Analysis

NYSE:ARD - New York Stock Exchange, Inc. - - Currency: USD

24.75  +0.63 (+2.61%)

After market: 24.72 -0.03 (-0.12%)

Fundamental Rating

2

Overall ARD gets a fundamental rating of 2 out of 10. We evaluated ARD against 22 industry peers in the Containers & Packaging industry. ARD has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ARD is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

ARD had positive earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -0.05%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 6.03%
PM (TTM) -0.08%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

There is no outstanding debt for ARD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ARD has an Altman-Z score of 0.62. This is a bad value and indicates that ARD is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of -34.80 indicates that ARD is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -34.8
Debt/FCF N/A
Altman-Z 0.62
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 2.77 indicates that ARD has no problem at all paying its short term obligations.
A Quick Ratio of 2.30 indicates that ARD has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 2.3

4

3. Growth

3.1 Past

ARD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.39%.
ARD shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -6.97% yearly.
ARD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.39%.
The Revenue has been decreasing by -1.05% on average over the past years.
EPS 1Y (TTM)-5.39%
EPS 3Y-6.97%
EPS 5YN/A
EPS Q2Q%21.62%
Revenue 1Y (TTM)9.39%
Revenue growth 3Y-7.83%
Revenue growth 5Y-1.05%
Sales Q2Q%16.69%

3.2 Future

The Earnings Per Share is expected to grow by 17.94% on average over the next years. This is quite good.
The Revenue is expected to grow by 8.07% on average over the next years. This is quite good.
EPS Next Y9.94%
EPS Next 2Y14.94%
EPS Next 3Y16.76%
EPS Next 5Y17.94%
Revenue Next Year10.92%
Revenue Next 2Y8.75%
Revenue Next 3Y8.72%
Revenue Next 5Y8.07%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ARD Yearly Revenue VS EstimatesARD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
ARD Yearly EPS VS EstimatesARD Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 15.66, ARD is valued correctly.
ARD's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.55.
Based on the Price/Forward Earnings ratio of 13.01, the valuation of ARD can be described as correct.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.30, ARD is valued a bit cheaper.
Industry RankSector Rank
PE 15.66
Fwd PE 13.01
ARD Price Earnings VS Forward Price EarningsARD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 5.25
ARD Per share dataARD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 200 300

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ARD's earnings are expected to grow with 16.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.58
PEG (5Y)N/A
EPS Next 2Y14.94%
EPS Next 3Y16.76%

3

5. Dividend

5.1 Amount

ARD has a Yearly Dividend Yield of 2.42%.
ARD's Dividend Yield is comparable with the S&P500 average which is at 2.39.
Industry RankSector Rank
Dividend Yield 2.42%

5.2 History

On average, the dividend of ARD grows each year by 12.62%, which is quite nice.
ARD has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)12.62%
Div Incr YearsN/A
Div Non Decr YearsN/A
ARD Yearly Dividends per shareARD Yearly Dividends per shareYearly Dividends per share 2017 2020 2021 0.5 1 1.5

5.3 Sustainability

The earnings of ARD are negative and hence is the payout ratio. ARD will probably not be able to sustain this dividend level.
The dividend of ARD is growing, but earnings are growing more, so the dividend growth is sustainable.
DP-2350%
EPS Next 2Y14.94%
EPS Next 3Y16.76%

Ardagh Group SA

NYSE:ARD (10/5/2021, 8:42:00 PM)

After market: 24.72 -0.03 (-0.12%)

24.75

+0.63 (+2.61%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryContainers & Packaging
Earnings (Last)N/A N/A
Earnings (Next)02-18 2022-02-18/bmo
Inst Owners0.01%
Inst Owner Change92.65%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap461.83M
Analysts84
Price Target30.45 (23.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.42%
Yearly Dividend0.6
Dividend Growth(5Y)12.62%
DP-2350%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 15.66
Fwd PE 13.01
P/S 0.06
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 5.25
EPS(TTM)1.58
EY6.38%
EPS(NY)1.9
Fwd EY7.69%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS383.23
BVpS-14.15
TBVpSN/A
PEG (NY)1.58
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.05%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 6.03%
PM (TTM) -0.08%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity -34.8
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 2.3
Altman-Z 0.62
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.39%
EPS 3Y-6.97%
EPS 5YN/A
EPS Q2Q%21.62%
EPS Next Y9.94%
EPS Next 2Y14.94%
EPS Next 3Y16.76%
EPS Next 5Y17.94%
Revenue 1Y (TTM)9.39%
Revenue growth 3Y-7.83%
Revenue growth 5Y-1.05%
Sales Q2Q%16.69%
Revenue Next Year10.92%
Revenue Next 2Y8.75%
Revenue Next 3Y8.72%
Revenue Next 5Y8.07%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A